文献速递泌尿生殖与妇科肿瘤放疗头颈部肿瘤放疗放疗物理与技术

口服Chk1抑制剂CCT244747增强膀胱癌与头颈癌细胞系放射敏感性

An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation.
PubMed 文献 · Radiother Oncol · 2017-01-25

该研究在膀胱癌和头颈癌细胞系及移植瘤模型中,评估了首个口服生物利用的Chk1抑制剂CCT244747联合放疗的增敏作用。结果显示CCT244747在体外增敏细胞系,在体内导致肿瘤生长延迟并伴生存获益。其放射增敏机制与消除辐射诱导的G2期阻滞和提前进入有丝分裂有关。

要点

  • CCT244747是首个口服生物利用的Chk1抑制剂,在膀胱癌和头颈癌细胞系中具有放射增敏作用。
  • 体内移植瘤模型中,CCT244747联合放疗导致肿瘤生长延迟并伴生存获益。
  • 放射增敏机制为消除辐射诱导的G2期阻滞并促使细胞提前进入有丝分裂。

核心结论

  • CCT244747是一种强效且特异的Chk1抑制剂,可口服给药,能增敏肿瘤细胞系,是与放疗联合应用的新临床治疗选择。

研究设计与样本

  • 研究使用一组膀胱癌和头颈癌细胞系,在体外和体内模型中监测CCT244747联合放疗的效果。

主要发现

  • CCT244747在体外增敏癌细胞系对放疗的敏感性。
  • 在癌症移植瘤模型中,CCT244747联合放疗导致肿瘤生长延迟,并伴有生存获益。
  • 放射增敏由消除辐射诱导的G2期阻滞和提前进入有丝分裂所引发。

临床怎么用

  • CCT244747可口服给药,作为Chk1抑制剂与放疗联合,可能成为膀胱癌和头颈癌的临床治疗新策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Chk1 inhibition increases cell sensitivity to both chemotherapy and radiotherapy in several tumour types and is, therefore, a promising anti-cancer approach. Although several Chk1 inhibitors have been developed, their clinical progress has been hampered by low bioavailability and off-target toxicities. MATERIALS AND METHODS: We characterized the radiosensitizing activity of CCT244747, the first orally bioavailable Chk1 inhibitor. We used a panel of bladder and head and neck cancer cell lines and monitored the effect of combining CCT244747 with radiation both in in vitro and in vivo models. RESULTS: CCT244747 sensitized cancer cell lines to radiation in vitro and resulted in a growth delay in cancer xenograft models associated with a survival benefit. Radiosensitization was elicited by abrogation of the radiation-induced G2 arrest and premature entry into mitosis. CONCLUSIONS: CCT244747 is a potent and specific Chk1 inhibitor that can be administered orally. It radiosensitizes tumour cell lines and represents a new therapy for clinical application in combination with radiotherapy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Patel R, Barker HE, Kyula J, et al. An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation. Radiother Oncol. 2017. PMID: 28131548. doi:10.1016/j.radonc.2016.12.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。